Skip to main content

Bronchiectasis Linked to Higher Mortality in COPD Patients


Smoking, pulmonary hypertension, and a decline in lung function are associated with an increased risk of death in people with chronic obstructive pulmonary disease (COPD). Now researchers in Spain have added another potential risk factor: the presence and severity of bronchiectasis.
Compared with unaffected patients with COPD, patients with bronchiectasis had more than double the risk of dying than those without, according to a prospective, observational study published online February 8 in the American Journal of Respiratory and Critical Care Medicine.
Miguel Angel Martínez-García, MD, from the Pneumology Service at the University and Polytechnic La Fe Hospital in Valencia, Spain, and colleagues assessed 201 participants with moderate to severe COPD from a consecutive series of outpatients diagnosed at 1 of 2 specialty clinics in Spain. The mean age of participants was 70 years, and 91% were men. A majority (77%) featured radiologic signs of emphysema. Patients were diagnosed between January 2004 and February 2007.
"Patients with bronchiectasis in our series were 2.5 times more likely to die than those without bronchiectasis, independently of other variables," the researchers write.
Of the participants, 115 (57%) presented with bronchiectasis, which is defined "as a permanent and progressive dilation of the airways." The researchers followed up the participants every 3 to 6 months for a median of 48 months. Mortality risk among these patients with bronchiectasis was higher compared with that for the 86 unaffected patients (unadjusted hazard ratio, 4.07; 95% confidence interval, 1.9 - 8.7; P = .0001).
Bronchiectasis remained an independent factor after adjustment for dyspnea (Medical Research Council Dyspnea Scale), partial pressure of oxygen, body mass index, presence of potentially pathogenic microorganisms in sputum, presence of daily sputum production, number of severe exacerbations and peripheral albumin, and ultrasensitive C-reactive protein concentrations (adjusted hazard ratio, 2.54; 95% confidence interval, 1.16 - 5.56; P = .02). Age, Charlson Index, and postbronchodilator forced expiratory volume in 1 second (%) were also significantly associated with mortality in the adjusted model.
"The results of this study confirm a high prevalence of bronchiectasis in moderate-to-severe COPD patients and suggest that bronchiectasis is independently associated with an increased risk of all-cause mortality in these patients," the authors write.
The 51 deaths during follow-up were attributed to respiratory causes (32 patients), cardiovascular disease (11), malignant disease (5), and other causes (3 patients). Other factors that can influence mortality in patients with COPD were not assessed (eg, inactivity or pulmonary hypertension), which is a limitation of the study.
Use of bronchiectasis as a new factor for prognosis would "have a major clinical impact," the authors note. Detection of bronchiectasis with high-resolution computed tomography scans is reliable, and, once identified, patients can be treated with effective therapy to combat the chronic bronchial inflammation and infection.
"The pathogenic vicious circle of infection-inflammation leading to the formation of bronchiectasis can probably be broken by the early identification of this subgroup of patients with COPD and bronchiectasis and the establishment of early treatment, probably focusing on bronchial colonization by [potentially pathogenic microorganisms]."
Therefore, high-resolution computed tomography chest imaging should be considered for patients with COPD who are at higher risk for bronchiectasis, according to the investigators. Severe disease, multiple or severe exacerbations of COPD, and chronic colonization by potentially pathogenic microorganisms can elevate the risk. Further studies are warranted to confirm the results and to clarify the association between bronchiectasis and COPD exacerbations, the authors note.
This study was supported by Praxis Pharmaceutical. The authors have disclosed no relevant financial relationships.

Comments

  1. Hi
    I am Benit Dalton , a member of some Medical coding & Billing community. I had landed on your site “http://latestrxsys.blogspot.in" and found the articles really worth reading. The quality of your content is so good, that it made me request you something. I love to write medical coding and billing articles and would like to contribute something for your site. I can give you an original guest post and if you want, you can suggest me the topic also and I will write accordingly. Not only that, I will give you the total rights to edit the article and modify it as per your needs.
    In response I expect you to give a link back to one of my endorser who helps me to continue my passion and serve individual sites and blogs like yours.

    Please let me know your thoughts. Waiting for your positive.

    Thanks
    Benito Dalton
    supercoder08@gmail.com

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...